Arecor Therapeutics (AREC) investor relations material

Strategic focus and market opportunity

• Developing advanced therapeutics for diabetes, obesity, and cardiometabolic diseases, targeting multi-billion dollar markets.

• Lead asset AT278 is an ultra-concentrated, ultra-rapid insulin designed to transform automated insulin delivery (AID) systems.

• Initial US total addressable market for AT278 estimated at $3B+, with potential to grow to $5B and further upside internationally.

• Multiple programs are partnered with leading pharmaceutical companies, de-risking the internal pipeline.

• Oral peptide delivery platform targets high-value markets, starting with oral GLP-1 drugs.

Product innovation and clinical results

• AT278 enables longer wear and smaller insulin pumps, addressing unmet needs for high insulin users.

• Demonstrated superior pharmacokinetic (PK) and pharmacodynamic (PD) profiles compared to NovoRapid and Humulin R U500 in both type 1 and type 2 diabetes.

• Phase 1 studies met all primary and secondary endpoints, showing faster onset and greater early insulin action.

• No safety signals detected in clinical trials.

• AT278 is positioned as the only insulin in development capable of enabling 7-day pump wear for most T1D and T2D patients.

Partnerships and commercialization

• Strategic partnership with Sequel Med Tech to co-develop next-generation, longer-wear AID systems.

• Sequel’s Twiist AID system, FDA approved and launched in 2025, is optimized for use with AT278.

• Both companies have committed $1.3M each to fund Phase 2 enabling studies, with pivotal Phase 2 trial targeted for 2H 2026.

• Ongoing discussions with additional insulin pump device companies to expand partnerships.